Successful Human Infection with P. falciparum Using Three Aseptic Anopheles stephensi Mosquitoes: A New Model for Controlled Human Malaria Infection

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Laurens, Matthew B ^a   Billingsley, Peter ^b   Richman, Adam ^b   Eappen, Abraham G ^b   Adams, Matthew ^a   Li, Tao ^b   Chakravarty, Sumana ^b   Gunasekera, Anusha ^b   Jacob, Christopher G ^a   Sim, B Kim Lee ^b,c   Edelman, Robert ^a   Plowe, Christopher V ^a   Hoffman, Stephen L ^b   Lyke, Kirsten E ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b SANARIA INC   (United States)

^c Protein Potential LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; MALARIA VACCINE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ANALYTIC METHOD; ANOPHELES STEPHENSI; ARTHRALGIA; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED HUMAN MALARIA INFECTION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYNAMICS; ERYTHEMA; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HYPOGLYCEMIA; IMMUNOGENICITY; INSECT BITE; MALAISE; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; MICROSCOPY; MYALGIA; NAUSEA; NONHUMAN; PAIN; PARASITE IDENTIFICATION; PARASITE TRANSMISSION; PARASITEMIA; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; QUANTITATIVE DIAGNOSIS; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SKIN INDURATION; SPOROZOITE; THROMBOCYTOPENIA; URTICARIA; VALIDATION STUDY;

ADOLESCENT; ADULT; ANIMALS; ANOPHELES; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84880461376     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068969     Document Type: Article

References (55)

1. Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, et al. (1986) Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 35: 66-68.
2. Herrington DA, Clyde DF, Murphy JR, Baqar S, Levine MM, et al. (1988) A model for Plasmodium falciparum sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite vaccines. Trop Geogr Med 40: 124-127.
3. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, et al. (1987) Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1: 1277-1281.
4. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, et al. (1987) Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328: 257-259 10.1038/328257a0 [doi].
5. Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P, (1999) Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 60: 831-836.
6. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, et al. (1997) Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 175: 915-920.
7. Epstein JE, Rao S, Williams F, Freilich D, Luke T, et al. (2007) Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 196: 145-154.
8. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, et al. (2001) Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183: 640-647.
9. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, et al. (2007) A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine 25: 5359-5366 10.1016/j.vaccine.2007.05.005 [doi].
10. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, et al. (2008) Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26: 2191-2202 10.1016/j.vaccine.2008.02.048 [doi].
11. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, et al. (2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 200: 337-346 10.1086/600120 [doi].
12. Malaria 2010: more ambition and accountability please. Lancet 375: 1407.
13. Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, et al. (2009) Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine 27: 5719-5725.
14. Laurens MB, Roestenberg M, Moorthy VS (2012) A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine. 10.1016/j.vaccine.2012.04.088 [doi].
15. Driver JR, Gammel JA, Darnosh LJ (1926) Malaria treatment central nervous system "syphilis". Journal of the American Medical Association (lxxxvii), 1921, Cited in Bunker 'Recent treatment of general paralysis'.
16. Brown EM, (2000) Why Wagner-Juaregg won the Nobel Prize for discovering Malaria Therapy for General Paresis of the Insane. Journal of Psychiatry xi: 371-382.
17. Clyde DF, Most H, McCarthy VC, Vanderberg JP, (1973) Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266: 169-177.
18. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW, (1974) Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 68: 258-259.
19. Sauerwein RW, Roestenberg M, Moorthy VS, (2011) Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 11: 57-64 10.1038/nri2902 [doi].
20. Maguire T, (1970) The laboratory transmission of Coxsackie A6 virus by mosquitoes. J Hyg (Lond) 68: 625-630.
21. Weissenbock H, Hubalek Z, Bakonyi T, Nowotny N, (2010) Zoonotic mosquito-borne flaviviruses: worldwide presence of agents with proven pathogenicity and potential candidates of future emerging diseases. Vet Microbiol 140: 271-280 10.1016/j.vetmic.2009.08.025 [doi].
22. Lyke KE, Laurens M, Adams M, Billingsley PF, Richman A, et al. (2010) Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One 5: e13490 10.1371/journal.pone.0013490 [doi].
23. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, et al. (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8 T cell immunity. Science 334: 475-480. science. 10.1126/science.1211548 [doi].
24. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM, (2008) Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 371: 923-931.
25. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, et al. (2010) Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6: 97-106.
26. Nieman AE, de Mast Q, Roestenberg M, Wiersma J, Pop G, et al. (2009) Cardiac complication after experimental human malaria infection: a case report. Malar J 8: 277.
27. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, et al. (2009) Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4: e5254.
28. Gunderson JH, Sogin ML, Wollett G, Hollingdale M, de la Cruz VF, et al. (1987) Structurally distinct, stage-specific ribosomes occur in Plasmodium. Science 238: 933-937.
29. Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D, et al. (2005) Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 191: 619-626 10.1086/427243 [doi].
30. Roestenberg M, O'Hara GA, Duncan CJ, Epstein JE, Edwards NJ, et al. (2012) Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One 7: e38434 10.1371/journal.pone.0038434 [doi].
31. Ross R, Thomson D, (1910) Some Enumerative Studies on Malaria Fever. Proc R Soc Lond 83: 159-173.
32. World Health Organization (2000) Severe falciparum malaria. Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 94Suppl 1: S1-90.
33. Menard R, (2000) The journey of the malaria sporozoite through its hosts: two parasite proteins lead the way. Microbes Infect 2: 633-642.
34. Jeffery GM, Young MD, Burgess RW, Eyles DE, (1959) Early activity in sporozoite-induced Plasmodium falciparum infections. Ann Trop Med Parasitol 53: 51-58.
35. Murphy JR, Clyde DF, Herrington DA, Baqar S, Davis JR, et al. (1990) Continuation of chloroquine-susceptible Plasmodium falciparum parasitemia in volunteers receiving chloroquine therapy. Antimicrob Agents Chemother 34: 676-679.
36. George J, Blanford S, Domingue MJ, Thomas MB, Read AF, et al. (2011) Reduction in host-finding behaviour in fungus-infected mosquitoes is correlated with reduction in olfactory receptor neuron responsiveness. Malar J 10: 219 ---10.1186/1475-2875-10-219 [doi].
37. Blanford S, Chan BH, Jenkins N, Sim D, Turner RJ, et al. (2005) Fungal pathogen reduces potential for malaria transmission. Science 308: 1638-1641 10.1126/science.1108423 [doi].
38. Yoshida S, Ioka D, Matsuoka H, Endo H, Ishii A, (2001) Bacteria expressing single-chain immunotoxin inhibit malaria parasite development in mosquitoes. Mol Biochem Parasitol 113: 89-96.
39. Medica DL, Sinnis P, (2005) Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected anopheline mosquitoes. Infect Immun 73: 4363-4369.
40. Jarra W, Snounou G, (1998) Only viable parasites are detected by PCR following clearance of rodent malarial infections by drug treatment or immune responses. Infect Immun 66: 3783-3787.
41. McCutchan TF, Li J, McConkey GA, Rogers MJ, Waters AP, (1995) The cytoplasmic ribosomal RNAs of Plasmodium spp. Parasitol Today 11: 134-138.
42. Eichner M, Diebner HH, Molineaux L, Collins WE, Jeffery GM, et al. (2001) Genesis, sequestration and survival of Plasmodium falciparum gametocytes: parameter estimates from fitting a model to malariatherapy data. Trans R Soc Trop Med Hyg 95: 497-501.
43. Collins WE, Jeffery GM, (2003) A retrospective examination of mosquito infection on humans infected with Plasmodium falciparum. Am J Trop Med Hyg 68: 366-371.
44. McKenzie FE, Jeffery GM, Collins WE, (2007) Gametocytemia and fever in human malaria infections. J Parasitol 93: 627-633 10.1645/GE-1052R.1 [doi].
45. Andrews L, Andersen RF, Webster D, Dunachie S, Walther RM, et al. (2005) Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg 73: 191-198.
46. Bejon P, Andrews L, Hunt-Cooke A, Sanderson F, Gilbert SC, et al. (2006) Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density. Malar J 5: 104 10.1186/1475-2875-5-104 [doi].
47. Rockett RJ, Tozer SJ, Peatey C, Bialasiewicz S, Whiley DM, et al. (2011) A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers. Malar J 10: 48 10.1186/1475-2875-10-48 [doi].
48. Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, et al. (2011) A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 29: 7514-7522 10.1016/j.vaccine.2011.03.083 [doi].
49. Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, et al. (2008) Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 3: e1493 10.1371/journal.pone.0001493 [doi].
50. Hermsen CC, de Vlas SJ, van Gemert GJ, Telgt DS, Verhage DF, et al. (2004) Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg 71: 196-201.
51. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, et al. (2011) Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377: 1770-6 10.1016/S0140-6736(11)60360-7 [doi].
52. Lavstsen T, Magistrado P, Hermsen CC, Salanti A, Jensen AT, et al. (2005) Expression of Plasmodium falciparum erythrocyte membrane protein 1 in experimentally infected humans. Malar J 4: 21 10.1186/1475-2875-4-21 [doi].
53. McCall MB, Netea MG, Hermsen CC, Jansen T, Jacobs L, et al. (2007) Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J Immunol 179: 162-171.
54. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, et al. (2009) Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361: 468-477 10.1056/NEJMoa0805832 [doi].
55. Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, et al. (2013) Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 88: 5-13 10.4269/ajtmh.2012.12-0613 [doi].